AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9604993 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 secreting helper T lymphocyte precursors (HTLp) frequency testing
Number of subjects: 58
Study 9604993 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic T lymphocyte precursors (CTLp) frequency testing
Number of subjects: 58
Study 9604993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined testing of HTLp and CTLp frequencies
Number of subjects: 58
Study 7544207 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia for 1 hour
Number of subjects: 96
Study 7544207 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 96
Study 7544207 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave hyperthermia
Number of subjects: 96
Study 2666475 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced learning
Number of subjects: 0
Study 2666475 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 2666475 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant therapy
Number of subjects: 0
Study 344019 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐‐M (decreasing daily dose of methadone in two equal doses given 12 hours apart)
Number of subjects: 22
Study 344019 — intervention group
Group type: COMPARATOR
Intervention: M‐‐PN (decreasing daily dose of methadone supplemented by propoxyphene napsylate)
Number of subjects: 22
Study 31096538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rectal indomethacin administration
Number of subjects: 162
Study 31096538 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose rectal indomethacin administration
Number of subjects: 162
Study 31096538 — intervention group
Group type: COMPARATOR
Intervention: Difficult cannulation as a risk factor
Number of subjects: 162
Study 26884344 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (tegafur, gimeracil, and oteracil)
Number of subjects: 829
Study 25552396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoma CRx intramedullary pin (IMP)
Number of subjects: 45
Study 25552396 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive locking midshaft superior plating (MIPPO)
Number of subjects: 45
Study 24362706 — intervention group
Group type: EXPERIMENTAL
Intervention: CocoaCHOC: 350 mg flavanols per serving
Number of subjects: 8
Study 24362706 — intervention group
Group type: COMPARATOR
Intervention: CHOC: 0 mg flavanols
Number of subjects: 8
Study 20352525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioenterics intragastric balloon (BIB)
Number of subjects: 33
Study 18986657 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton depression rating scale (HAMD)
Number of subjects: 0
Study 18986657 — intervention group
Group type: EXPERIMENTAL
Intervention: Montgomery‐Asberg depression rating scale (MADRS)
Number of subjects: 0
Study 18986657 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton anxiety rating scale (HAMA)
Number of subjects: 0
Study 17021748 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection (STARR)
Number of subjects: 68
Study 17021748 — intervention group
Group type: COMPARATOR
Intervention: Stapled anopexy (SA)
Number of subjects: 68
Study 17021748 — intervention group
Group type: EXPERIMENTAL
Intervention: STARR
Number of subjects: 68
Study 17021748 — intervention group
Group type: COMPARATOR
Intervention: SA
Number of subjects: 68
Study 15136218 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide treatment
Number of subjects: 34
Study 11318759 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMedicus centrifugal pump
Number of subjects: 1000
Study 11318759 — intervention group
Group type: COMPARATOR
Intervention: roller pump
Number of subjects: 1000
Study 9454350 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARTWEEL radiotherapy to 60 Gy (15 weekly fractions of 1.5 Gy)
Number of subjects: 665
Study 9454350 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy to 66 Gy (5 weekly fractions of 2 Gy)
Number of subjects: 665
Study 8094114 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily (OD)
Number of subjects: 123
Study 8094114 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.33 mg/kg three times daily (MD)
Number of subjects: 123
Study 3679647 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with low frequency (50 Hz) for 21 days
Number of subjects: 22
Study 3679647 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation with high frequency (2000 Hz) for 21 days
Number of subjects: 22
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily nebulised hypertonic saline (HTS 6%) with standard care
Number of subjects: 0
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day) with standard care
Number of subjects: 0
Study 31856887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of twice-daily nebulised HTS and carbocisteine with standard care
Number of subjects: 0
Study 29373476 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897 50 mg
Number of subjects: 142
Study 29373476 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI8897
Number of subjects: 142
Study 29373476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 26395174 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM/AML 40/10 mg
Number of subjects: 0
Study 26395174 — intervention group
Group type: COMPARATOR
Intervention: PER/AML 8/10 mg
Number of subjects: 0
Study 25421512 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 64
Study 25421512 — intervention group
Group type: COMPARATOR
Intervention: acamprosate
Number of subjects: 64
Study 23025349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with slow, medium, and fast dissolution rates.
Number of subjects: 0
Study 23025349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with varying dissolution rates.
Number of subjects: 0
Study 20595477 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-ibuprofen 400 mg every 6 hours for 72 hours
Number of subjects: 60
Study 20595477 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 6 hours for 72 hours
Number of subjects: 60
Study 18538997 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey
Number of subjects: 720
Study 18538997 — intervention group
Group type: COMPARATOR
Intervention: Mail survey
Number of subjects: 720
Study 15833505 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the PUF questionnaire
Number of subjects: 0
Study 15833505 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish version of the PUF questionnaire (retest)
Number of subjects: 0
Study 15833505 — intervention group
Group type: COMPARATOR
Intervention: English version of the PUF questionnaire
Number of subjects: 0
Study 12927659 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 18
Study 10685829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 0
Study 10685829 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SASP)
Number of subjects: 0
Study 8863236 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH, 0.2 mg/kg/d)
Number of subjects: 22
Study 8863236 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 1321655 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg
Number of subjects: 24
Study 1321655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6547612 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal cinchocaine with morphine hydrochloride 2.5 mg
Number of subjects: 20
Study 6547612 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal cinchocaine alone
Number of subjects: 20
Study 3453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (SC) treatment
Number of subjects: 0
Study 3453169 — intervention group
Group type: COMPARATOR
Intervention: Referred care (RC) treatment
Number of subjects: 0
Study 3453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 0
Study 3453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure (DBP)
Number of subjects: 0
Study 3453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrandomization reduction in SBP
Number of subjects: 0
Study 3453169 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced DBP
Number of subjects: 0
Study 29251700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH) 30 mg BID
Number of subjects: 150
Study 29251700 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg BID
Number of subjects: 150
Study 27708113 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session quit advice (15 min) plus a single training session in yogic breathing exercises
Number of subjects: 1213
Study 27708113 — intervention group
Group type: COMPARATOR
Intervention: Very brief quit advice (1 min) alone
Number of subjects: 1213
Study 26246907 — intervention group
Group type: EXPERIMENTAL
Intervention: vBloc
Number of subjects: 239
Study 26246907 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 239
Study 23913744 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior ketoconazole therapy
Number of subjects: 1050
Study 21939418 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly recombinant factor VIII prophylaxis, with up to two rescue doses per week
Number of subjects: 0
Study 21939418 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly prophylaxis
Number of subjects: 0
Study 21939418 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdose thrombin generation assessment
Number of subjects: 0
Study 19050582 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 222
Study 19050582 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 222
Study 16284230 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects
Number of subjects: 40
Study 16284230 — intervention group
Group type: COMPARATOR
Intervention: Elderly sedentary subjects
Number of subjects: 40
Study 16284230 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly fit subjects
Number of subjects: 40
Study 16284230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifelong exercise training
Number of subjects: 40
Study 11991797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremities (LEs) rehabilitation
Number of subjects: 53
Study 11991797 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremities (UEs) rehabilitation
Number of subjects: 53
Study 11991797 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (paretic arm and leg immobilized)
Number of subjects: 53
Study 11991797 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed increase
Number of subjects: 53
Study 9808909 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular haemodialysis
Number of subjects: 0
Study 9808909 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 7655779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention group
Number of subjects: 127
Study 7655779 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 127
Study 7655779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 2655259 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intravesical therapy (STIT) with 1% solution of Epodyl, given once per week for 6 weeks
Number of subjects: 114
Study 2655259 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intravesical therapy (LTIT) with 1% solution of Epodyl, consisting of STIT followed by an additional dose once a month for 2 years
Number of subjects: 114
Study 2655259 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intravesical therapy (STIT) for solitary tumors
Number of subjects: 114
Study 2655259 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intravesical therapy (LTIT) for solitary tumors
Number of subjects: 114
Study 875786 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (100 mg three times a day)
Number of subjects: 22
Study 875786 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (50 mg three times a day)
Number of subjects: 22
Study 30169969 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTRm amyloidosis patients
Number of subjects: 172
Study 25812725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local points (JOI‐LP)
Number of subjects: 68
Study 25812725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at distant points (MUS‐DP)
Number of subjects: 68
Study 25812725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local points (MUS‐LP)
Number of subjects: 68
Study 25812725 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at distant points (JOI‐DP)
Number of subjects: 68
Study 24092822 — intervention group
Group type: EXPERIMENTAL
Intervention: Function‐Focused Care for the Cognitively Impaired Intervention
Number of subjects: 103
Study 22851700 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Frequency Power (VLFP)
Number of subjects: 388
Study 22851700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Frequency Power (LFP)
Number of subjects: 388
Study 22851700 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbulence Slope (TS)
Number of subjects: 388
Study 22851700 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired Turbulence Slope (<2.5 ms per RR interval)
Number of subjects: 388
Study 20525780 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge with behavioral intervention
Number of subjects: 102
Study 20525780 — intervention group
Group type: COMPARATOR
Intervention: Behavioral intervention alone
Number of subjects: 102
Study 18427418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (VC: 1 000 mg vitamin C)
Number of subjects: 16
Study 18427418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18427418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 16153930 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg orally 12 and 3 hours before surgery)
Number of subjects: 102
Study 16153930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 14648739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral pelvic lymph node dissection (LPLD)
Number of subjects: 246
Study 14648739 — intervention group
Group type: COMPARATOR
Intervention: No lateral pelvic lymph node dissection (No LPLD)
Number of subjects: 246
Study 10613576 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 5, 10, or 20 mg (for children <40 kg) or 10, 20, or 40 mg (for children ≥40 kg) 3 times a day
Number of subjects: 78
Study 10613576 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa combination
Number of subjects: 78
Study 10613576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 7562679 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sodium diet with water loading (2290 ml in 3 1/2 hr) and competitive videogame stress test
Number of subjects: 48
Study 7562679 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 48
Study 1975484 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (70 micrograms/kg) with glycopyrrolate (15 micrograms/kg)
Number of subjects: 40
Study 1975484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 40
Study 7384332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 240
Study 7384332 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 240
Study 7384332 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and Diazepam
Number of subjects: 240
Study 7384332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 29476913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction
Number of subjects: 0
Study 29476913 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 0
Study 27801407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (daily 25 min sessions for 7 days, 2 MW, 0.63 microns)
Number of subjects: 30
Study 27801407 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone (control group)
Number of subjects: 30
Study 25080458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent lack-of-adherence model
Number of subjects: 0
Study 25080458 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic adaptation model
Number of subjects: 0
Study 22635125 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive intervention program based on social mediation, cooperative learning, and metacognition (3 months duration)
Number of subjects: 29
Study 22635125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 29
Study 20552094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis
Number of subjects: 42
Study 20552094 — intervention group
Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis
Number of subjects: 42
Study 20552094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis for new users
Number of subjects: 42
Study 20552094 — intervention group
Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis for new users
Number of subjects: 42
Study 20552094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorinated polyethylene elastomer (CPE) prosthesis for previous users
Number of subjects: 42
Study 20552094 — intervention group
Group type: COMPARATOR
Intervention: Silicone elastomer prosthesis for previous users
Number of subjects: 42
Study 19089285 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform
Number of subjects: 40
Study 19089285 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange oil
Number of subjects: 40
Study 19089285 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptol
Number of subjects: 40
Study 19089285 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 16111588 — intervention group
Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 65
Study 16111588 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating triple therapy (ATT)
Number of subjects: 65
Study 16111588 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CLI and ATT
Number of subjects: 65
Study 12022436 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV-TV (4 x 10(4) pfu/dose)
Number of subjects: 540
Study 12022436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 10819233 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg orally three times a day for 1 week
Number of subjects: 34
Study 10819233 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg orally three times a day for 4 weeks
Number of subjects: 34
Study 10819233 — intervention group
Group type: COMPARATOR
Intervention: Intravenous erythromycin 10 mg x kg(‐1) x h(‐1)
Number of subjects: 34
Study 10819233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 8991774 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve not identified intraoperatively (Group I)
Number of subjects: 800
Study 8991774 — intervention group
Group type: COMPARATOR
Intervention: Nerve identified intraoperatively (Group II)
Number of subjects: 800
Study 7038165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of sulfisoxazole
Number of subjects: 117
Study 7038165 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of sulfisoxazole
Number of subjects: 117
Study 7038165 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim 160 mg and sulfamethoxazole 800 mg
Number of subjects: 117
Study 7038165 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim 320 mg and sulfamethoxazole 1,600 mg
Number of subjects: 117
Study 7038165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 117
Study 31610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily (q.d.)
Number of subjects: 3685
Study 31610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 30 mg once daily (q.d.)
Number of subjects: 3685
Study 31610021 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3685
Study 31610021 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA)
Number of subjects: 3685
Study 31319590 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod protein hydrolysate (CPH) 2.5 g daily for 6 weeks
Number of subjects: 28
Study 31319590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31319590 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPH and placebo)
Number of subjects: 28
Study 31319590 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures for the whole group
Number of subjects: 28
Study 27717236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 28,000 IU once weekly for 24 weeks
Number of subjects: 71
Study 27717236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 25885668 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based inspiratory muscle training (IMT) programme at intensity >30% maximum inspiratory pressure (PImax) for 7 weeks
Number of subjects: 68
Study 25885668 — intervention group
Group type: COMPARATOR
Intervention: Control group with training at intensity <15% PImax for 7 weeks
Number of subjects: 68
Study 24522786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention involving multidisciplinary care, education, and regular monitoring
Number of subjects: 60
Study 24522786 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 24522786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 60